The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss, 10 out of 11 have shown improvements after being treated with a gene therapy. “What is really ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...
Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Day One Biopharmaceuticals (DAWN – Research Report) yesterday. The company’s ...
Pharmaceutical Technology on MSN6h
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contractSamsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) yesterday and set a price target ...
On February 18, 2025, a panel of the U.S. Court of Appeals for the First Circuit unanimously decided that in order to transform an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback